Also trades as: AGY.L (LSE) · $vol 0M
AGYTF OTC
Allergy Therapeutics plc
1W: +0.0%
1M: +0.0%
3M: +7.1%
YTD: +36.4%
1Y: +76.5%
3Y: -38.3%
5Y: -31.8%
$0.15
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$68M
+4.2% ▲
5Y CAGR: -4.8%
Total Liabilities
$131M
+115.0% ▲
5Y CAGR: +25.4%
Shareholders Equity
-$39M
-1143.5% ▼
Cash & Investments
$18M
+38.1% ▲
5Y CAGR: -13.8%
Total Debt
$60M
+93.9% ▲
5Y CAGR: +37.6%
Net Debt
$65M
+255.3% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $40M | $21M | $15M | $13M | $18M |
| Short-Term Investments | $0 | $0 | $200K | $0 | $0 |
| Cash & ST Investments | $40M | $21M | $15M | $13M | $18M |
| Net Receivables | $6M | $9M | $2M | $7M | $11M |
| Inventory | $11M | $11M | $12M | $13M | $14M |
| Other Current Assets | -$640K | -$3M | $3M | $738K | -$8M |
| Total Current Assets | $58M | $42M | $34M | $33M | $35M |
| Property, Plant & Equip. | $20M | $20M | $23M | $24M | $24M |
| Goodwill & Intangibles | $5M | $5M | $5M | $5M | $6M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Assets | $6M | $6M | $5M | $3M | $1M |
| Total Non-Current Assets | $30M | $31M | $33M | $31M | $33M |
| Total Assets | $88M | $74M | $67M | $65M | $68M |
| — Liabilities — | |||||
| Accounts Payable | $3M | $4M | $4M | $4M | $4M |
| Short-Term Debt | $963K | $952K | $648K | $600K | $405K |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $25K | -$93K | $178K | $10M | $29M |
| Total Current Liabilities | $18M | $18M | $19M | $21M | $37M |
| Long-Term Debt | $2M | $1M | $26M | $22M | $53M |
| Other Non-Current Liab. | $11M | $8M | $11M | $11M | $10M |
| Total Non-Current Liabilities | $21M | $17M | $46M | $41M | $69M |
| Total Liabilities | $40M | $35M | $65M | $61M | $131M |
| — Equity — | |||||
| Common Stock | $641K | $644K | $679K | $5M | $7M |
| Retained Earnings | -$107M | -$119M | -$162M | -$199M | -$268M |
| Accumulated OCI | $43M | $43M | $44M | $43M | $10M |
| Total Stockholders Equity | $49M | $38M | $2M | $4M | -$39M |
| Total Liabilities & Equity | $88M | $74M | $67M | $65M | $93M |
| — Key Metrics — | |||||
| Total Debt | $11M | $11M | $36M | $31M | $60M |
| Net Debt | -$29M | -$10M | $21M | $18M | $65M |
| Total Investments | $0 | $0 | $200K | $0 | $0 |